معرفی
James M. Burns Jr., PhD, is a Professor in the Department of Microbiology & Immunology at Drexel University College of Medicine. His research program focuses on malaria vaccine development, particularly on improving subunit vaccines targeting multiple stages of the Plasmodium parasite life cycle.
Dr. Burns earned his PhD from Hahnemann University in 1989. His laboratory investigates the host immune response to malaria parasites and develops highly immunogenic, multi-subunit, multi-stage vaccines. His work bridges basic research using rodent malaria models with translational studies focused on human malaria.
- Primary Research Focus: Development of protective immunity against malaria induced by immunization with defined subunit vaccines targeting pre-erythrocytic stage, blood-stage and sexual stage parasites
- Current Projects: Evaluating vaccine candidates including merozoite surface protein 2 (PfMSP2), reticulocyte-binding protein homologue 5 (PfRh5), the 25 kDa sexual stage antigen (Pfs25), and circumsporozoite protein
- Methodology: Utilizing Plasmodium yoelii and Plasmodium chabaudi rodent models alongside in vitro studies of P. falciparum blood-stage parasites
Dr. Burns' publication record shows consistent productivity with research spanning from fundamental parasite biology to advanced vaccine development. His recent work (2020-2024) demonstrates continued innovation in malaria vaccine design, particularly in developing chimeric antigens and multi-stage vaccine formulations. His research addresses two critical challenges in malaria vaccinology: improving subunit vaccine immunogenicity and developing multi-antigen formulations without compromising individual component efficacy.
Scientific Recognition:
- Institutional Service Award, Drexel University College of Medicine (2023)
Dr. Burns has mentored graduate students including Hayley Klingenberg and research associates like Amy Ott, PhD. His laboratory has made significant contributions to understanding how to enhance the immunogenicity of malaria vaccine candidates through innovative approaches such as engineering parasite-specific carrier proteins. His work provides a solid foundation for subsequent safety and immunogenicity testing in human subjects, potentially leading to a combined pre-erythrocytic-stage/blood-stage/sexual-stage malaria vaccine that could reduce clinical disease severity and block transmission.
